![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Combination of Grazoprevir (MK-5172), an NS3 Inhibitor, and MK-8408, an NS5A Inhibitor, Presents a High Genetic Barrier to Resistance in HCV Genotypes 1a and 3a
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Fred Lahser1, Karin Bystol1, Stephanie Curry1, Patricia McMonagle1, Rong Liu1, Ellen Xia2, Robert Chase1, Stuart Black1, Eric Ferrari1,Ling Tong3, Wensheng Yu3, Joseph Kozlowski3 and Ernest Asante-Appiah1
Departments of 1Infectious Diseases, 2In Vitro Pharmacology, 3Medicinal Chemistry, Merck & Co., Inc., Whitehouse Station, NJ, USA
![AASLD1.gif](../images/111414/111414-7/AASLD1.gif)
![AASLD2.gif](../images/111414/111414-7/AASLD2.gif)
![AASLD3.gif](../images/111414/111414-7/AASLD3.gif)
![AASLD4.gif](../images/111414/111414-7/AASLD4.gif)
![AASLD5.gif](../images/111414/111414-7/AASLD5.gif)
![AASLD6.gif](../images/111414/111414-7/AASLD6.gif)
![AASLD7.gif](../images/111414/111414-7/AASLD7.gif)
![AASLD8.gif](../images/111414/111414-7/AASLD8.gif)
![AASLD9.gif](../images/111414/111414-7/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|